GREGORY GATTO, PHD

Project Technical Lead/Liaison

Gregory Gatto is a senior research pharmacologist in RTI International’s Center for Global Health. He has more than 20 years of drug development experience and has directed scientific research programs from target validation (TV) to first-time-in-human (FTIH) in therapeutic areas including psychiatry, neurology, respiratory, metabolic and gastrointestinal diseases. He managed research strategies that repurposed unwanted clinical endpoints into new clinical indications. He has established an excellent track record in submitting dossiers to regulatory agencies and has extensive expertise in nonclinical safety assessment. Before joining RTI, he held the following positions: senior director of behavioral pharmacology at Melior Discovery, CEO/co-founder of Biolucidation LLC, cofounder of AlphaSyx Therapeutics, senior director of preclinical pharmacology at Targacept, and an independent research contractor for Aventis Pharma. He did his postdoctoral fellowship at Wake Forest University, focusing on profiling drug-attenuating agents in animal models of addiction. His graduate studies at Indiana University were focused on mapping drug reinforcing sites in brain regions of rodents using an innovative drug delivery device and preclinical evaluation of potential pharmacotherapies in the treatment of alcoholism. Dr. Gatto has produced more than 100 publications, patents, and presentations.